| Host |
Mouse |
| Klon |
BP53-12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Nucleus |
p53
|
Zytomed Systems GmbH |
BP53-12 |
1 ml |
Concentrate |
RUO |
MSK020 |
-
|
| Host |
Mouse |
| Klon |
BP53-12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Nucleus |
p53
|
Zytomed Systems GmbH |
BP53-12 |
0.5 ml |
Concentrate |
RUO |
MSK020-05 |
-
|
| Host |
Mouse |
| Klon |
DO7 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b |
| Lokalisation |
Nucleus |
p53
|
Diagnostic Biosystems |
DO7 |
6 ml |
Ready-to-use |
CE/IVD |
PDM013 |
-
|
| Host |
Rabbit |
| Klon |
EP9 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Breast cancer, colon cancer |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nuclear |
p53
|
Biocare Medical |
EP9 |
6 ml |
Ready-to-use |
CE/IVD |
PME298AA |
-
|
| Host |
Mouse |
| Klon |
DO-7 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human wild type p53 protein expressed in E. coli |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
DO-7 |
1.0 ml |
Concentrate |
CE/IVD |
Z2029ML |
-
|
| Host |
Mouse |
| Klon |
DO-7 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human wild type p53 protein expressed in E. coli |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
DO-7 |
7 ml |
Ready-to-use |
CE/IVD |
Z2029MP |
-
|
| Host |
Mouse |
| Klon |
DO-7 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human wild type p53 protein expressed in E. coli |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
DO-7 |
0.5 ml |
Concentrate |
CE/IVD |
Z2029MS |
-
|
| Host |
Mouse |
| Klon |
DO-7 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human wild type p53 protein expressed in E. coli |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
DO-7 |
0.1 ml |
Concentrate |
CE/IVD |
Z2029MT |
-
|
| Host |
Rabbit |
| Klon |
ZR153 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human wild type p53 protein |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
ZR153 |
1 ml |
Concentrate |
CE/IVD |
Z2466RL |
-
|
| Host |
Rabbit |
| Klon |
ZR153 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human wild type p53 protein |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
ZR153 |
7 ml |
Ready-to-use |
CE/IVD |
Z2466RP |
-
|
| Host |
Rabbit |
| Klon |
ZR153 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human wild type p53 protein |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
ZR153 |
0.5 ml |
Concentrate |
CE/IVD |
Z2466RS |
-
|
| Host |
Rabbit |
| Klon |
ZR153 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human wild type p53 protein |
| Lokalisation |
Nucleus |
p53
|
Zeta Corporation |
ZR153 |
0.1 ml |
Concentrate |
CE/IVD |
Z2466RT |
-
|
| Host |
Mouse |
| Klon |
DO-1 |
| Format |
Purified |
| Methode |
F, P, EL, WB, IP |
| Positivkontrolle |
Colon or Breast Carcinoma |
| Verdünnung |
1:25 (P) |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant human p53 |
p53 (KIP2) (aa20-25)
|
Zytomed Systems GmbH |
DO-1 |
100 µg |
Purified |
RUO |
616-0013 |
-
|
| Host |
Mouse |
| Klon |
DO-7 |
| Format |
Purified |
| Methode |
F, P, WB, IP, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon or Breast Carcinoma |
| Verdünnung |
1:1000 (P) |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
Recombinant human p53 |
p53 (KIP2) (aa20-25)
|
Zytomed Systems GmbH |
DO-7 |
100 µg |
Purified |
RUO |
616-0017 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Hydatid Mole, Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from N-terminus of human p57/kip2 protein |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
516-18990 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Hydatid Mole, Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from N-terminus of human p57/kip2 protein |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
516-18992 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Hydatid Mole, Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from N-terminus of human p57/kip2 protein |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
516-18994 |
-
|
| Host |
Mouse |
| Klon |
57PO6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2b, κ |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
1 ml |
Concentrate |
CE/IVD |
MOB291 |
-
|
| Host |
Mouse |
| Klon |
57PO6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2b, κ |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB291-01 |
-
|
| Host |
Mouse |
| Klon |
57PO6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2b, κ |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB291-05 |
-
|
| Host |
Mouse |
| Klon |
57PO6 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b, κ |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
6 ml |
Ready-to-use |
CE/IVD |
PDM205 |
-
|
| Host |
Mouse |
| Klon |
57PO6 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2b, κ |
| Lokalisation |
Nucleus |
p57 (KIP2)
|
Diagnostic Biosystems |
57PO6 |
25 ml |
Ready-to-use |
CE/IVD |
PDM205-25 |
-
|
| Host |
Mouse |
| Klon |
KP10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma or placenta. |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p57Kip2 protein |
| Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
1ml |
Concentrate |
CE/IVD |
Z2173ML |
-
|
| Host |
Mouse |
| Klon |
KP10 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma or placenta. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p57Kip2 protein |
| Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2173MP |
-
|
| Host |
Mouse |
| Klon |
KP10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma or placenta. |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p57Kip2 protein |
| Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2173MS |
-
|
| Host |
Mouse |
| Klon |
KP10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma or placenta. |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human p57Kip2 protein |
| Lokalisation |
Nucleus |
p57Kip2
|
Zeta Corporation |
KP10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2173MT |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal Prostate |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Nucleus |
p63
|
Zytomed Systems GmbH |
4A4 |
16 ml |
Ready-to-use |
RUO |
BMS052 |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
0.1 ml |
Concentrate |
CE/IVD |
CM163A |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
0.5 ml |
Concentrate |
CE/IVD |
CM163B |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
1 ml |
Concentrate |
CE/IVD |
CM163C |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
6 ml |
Ready-to-use |
CE/IVD |
PM163AA |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a kappa |
| Lokalisation |
Nucleus |
p63
|
Biocare Medical |
4A4 |
25 ml |
Ready-to-use |
CE/IVD |
PM163H |
-
|
| Host |
Rabbit |
| Klon |
DBR16.1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma, tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human p63 protein fragment |
| Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
1 ml |
Concentrate |
CE/IVD |
RMAB086 |
-
|
| Host |
Rabbit |
| Klon |
DBR16.1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma, tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human p63 protein fragment |
| Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB086-01 |
-
|
| Host |
Rabbit |
| Klon |
DBR16.1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma, tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human p63 protein fragment |
| Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB086-05 |
-
|
| Host |
Rabbit |
| Klon |
DBR16.1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human p63 protein fragment |
| Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD086 |
-
|
| Host |
Rabbit |
| Klon |
DBR16.1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Prostate carcinoma, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human p63 protein fragment |
| Lokalisation |
Nucleus |
p63
|
Diagnostic Biosystems |
DBR16.1 |
25 ml |
Ready-to-use |
CE/IVD |
RMPD086-25 |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
1.0 ml |
Concentrate |
RUO |
Z2003ML-R |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
7 ml |
Ready-to-use |
RUO |
Z2003MP-R |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
0.5 ml |
Concentrate |
RUO |
Z2003MS-R |
-
|
| Host |
Mouse |
| Klon |
4A4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
4A4 |
0.1 ml |
Concentrate |
RUO |
Z2003MT-R |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM70 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin or prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human p63 protein |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
1 ml |
Concentrate |
CE/IVD |
Z2380ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM70 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin or prostate. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human p63 protein |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
7 ml |
Ready-to-use |
CE/IVD |
Z2380MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM70 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin or prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human p63 protein |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
0.5 ml |
Concentrate |
CE/IVD |
Z2380MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM70 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Skin or prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human p63 protein |
| Lokalisation |
Nucleus |
p63
|
Zeta Corporation |
ZM70 |
0.1 ml |
Concentrate |
CE/IVD |
Z2380MT |
-
|
| Host |
Mouse + Rabbit |
| Klon |
4A4+EP42 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung squamous cell carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+Rabbit IgG |
| Lokalisation |
Nuclear and cytoplasmic |
p63 + Cytokeratin 5 (Lung Squamous-2 TM)
|
Biocare Medical |
4A4+EP42 |
6 ml |
Ready-to-use |
CE/IVD |
PM391DSAA |
-
|
| Host |
Rabbit |
| Klon |
ZR316 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Breast lobular carcinoma, melanom |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
| Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
1 ml |
Concentrate |
CE/IVD |
Z2620RL |
-
|
| Host |
Rabbit |
| Klon |
ZR316 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Breast lobular carcinoma, melanom |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
| Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
7 ml |
Ready-to-use |
CE/IVD |
Z2620RP |
-
|
| Host |
Rabbit |
| Klon |
ZR316 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Breast lobular carcinoma, melanom |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
| Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
0.5 ml |
Concentrate |
CE/IVD |
Z2620RS |
-
|
| Host |
Rabbit |
| Klon |
ZR316 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Breast lobular carcinoma, melanom |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Fragment (around aa 900-1,000) of human CTNND1 protei |
| Lokalisation |
Cytoplasm and membrane |
p120
|
Zeta Corporation |
ZR316 |
0.1 ml |
Concentrate |
CE/IVD |
Z2620RT |
-
|